Fischer Medical Ventures
40.45
-0.41(-1.00%)
Market Cap₹2,623.20 Cr
PE Ratio68.17
IndustryChemicals
Company Performance:
1D-1.00%
1M+13.78%
6M-60.04%
1Y-47.87%
5Y-47.87%
View Company Insightsright
More news about Fischer Medical Ventures
02Feb 26
Fischer Medical Ventures Reports Strong Q3FY26 Performance with Revenue Growth
Fischer Medical Ventures delivered impressive Q3FY26 consolidated performance with revenue reaching ₹10,109.52 lakhs and achieving net profit of ₹1,923.48 lakhs against previous year's loss. The company also announced key organizational changes including resignation of Company Secretary and Malaysian subsidiary restructuring initiative.
 no imag found
21Jan 26
Fischer Medical Ventures Approves Internal Group Reorganisation of Foreign Subsidiary Shares
Fischer Medical Ventures Limited announced that its Executive Business Committee approved the transfer of shares in foreign subsidiary PellucidCare Health Innovations Pte Ltd (Singapore) to wholly owned subsidiary FlynnCare Health Innovations Private Limited as part of internal group reorganisation. The transfer aims to improve administrative and operational efficiency while maintaining unchanged ultimate ownership, control, and economic interest in the foreign subsidiary, with no material impact on consolidated financials.
 no imag found
02Jan 26
Fischer Medical Ventures Limited Updates Board Committee Composition in Regulatory Filing
Fischer Medical Ventures Limited disclosed updated board committee compositions on January 02, 2026, detailing the structure of Audit, Nomination & Remuneration, and Risk Management committees. The committees comprise independent directors, executive management, and senior officers, with Mr. Khairy Jamaluddin Abu Bakar chairing two committees and Ms. Svetlana Rao Raviwada leading the Risk Management Committee.
 no imag found
28Oct 25
Fischer Medical Ventures Reports Robust Q2 Growth with 46-Fold Increase in Net Profit
Fischer Medical Ventures, a medical technology company, reported a significant financial performance boost in Q2. Net profit surged to 139.00 million rupees from 3.00 million rupees year-over-year, a 46-fold increase. Revenue more than doubled to 863.00 million rupees from 397.00 million rupees. The company also announced board changes, appointing Mr. Chan Sing En as Additional Non-Executive Independent Director and recommending Tan Sri Dato' Dr. Syed Jalaludin as Independent Director, both for five-year terms subject to shareholder approval.
 no imag found
Fischer Medical Ventures
40.45
-0.41
(-1.00%)
1 Year Returns:-47.87%
Industry Peers
Tata Chemicals
623.50
(-1.69%)
GHCL
457.40
(+1.27%)
TANFAC Industries
2,100.00
(-100.00%)
Chemplast Sanmar
253.15
(+3.07%)
Grauer & Weil
62.25
(-100.00%)
Thirumalai Chemicals
173.20
(+0.40%)